Velocity Clinical Research, has announced three key tech investments to expand its patient community, increase client engagement, and speed up drug development across all its 30 integrated locations. It is a fully integrated clinical site organization

In the past 12 months, Velocity has randomized 25,000 patients into phase II and III studies in the US. The tech investments will enable Velocity to be more efficient in managing studies, identifying patients for studies, and increasing the frequency of participation in studies.

In the first place, it has partnered with Advarra on a regulatory and compliance tech rollout, using their Clinical Conductor Enterprise-level clinical trial management system (CTMS), combined with eReg and eSource, to access data of over 500,000 patients across its national site network in just a few clicks.

Secondly, Master Control has been selected to provide its Quality Management System which is a leader in the industry, used by the Food and Drug Administration (FDA) and many sponsors. Consequently, Velocity’s patients and sponsor partners will benefit from its enhanced ability to support new innovations, improve quality and compliance, and enable greater site efficiency achieved through automated quality processes.

Thirdly Velocity has acquired TrierHealth, a secure platform enabling digital clinical trial execution whose R&D team operates out of Hyderabad, India, to develop patient-focused technology. TrierHealth’s founder, Raghu Punnamraju, will become Velocity’s chief technology officer. Punnamraju brings extensive software and industry experience, including eight years with Parexel Informatics, and turns at Intermountain Healthcare in Utah, and GE Healthcare.

Dr G Paul Evans, chief executive and president of Velocity Clinical Research, said, “We’re building a global community of patients who are engaged, advocate for participation in clinical research, and actively take part in multiple studies. Building and scaling a truly integrated clinical site business to support this requires a common technology stack to achieve consistency.  “We are setting a new standard of integration for the research site industry to better recruit and retain patients into clinical research, he added.